Theralase Technologies (TLT) Q3 2024 earnings summary

Executive summary

• Revenue for the nine months ended September 30, 2024, decreased 12% year-over-year to $622,984, with declines in both Canadian and US markets, but a significant increase in international sales.

• Gross margin as a percentage of sales improved to 47% from 49% year-over-year, attributed to increased sales in Q3.

• Net loss narrowed by 7% to $3,337,995, primarily due to reduced research and development expenses in the Drug Division.

• Study II interim data shows 61.9% of evaluable patients achieved complete response (CR), with 43.6% maintaining CR at 450 days, and no serious adverse events directly related to the study drug or device.

Financial highlights

• Total revenue declined 12% year-over-year, with Canadian revenue down 11%, US revenue down 29%, and international revenue up 1185%.

• Cost of sales decreased 9% to $332,136, resulting in a gross margin of $290,848.

• Selling expenses increased 33% due to higher sales salaries and advertising.

• Administrative expenses decreased 11% due to lower general and administrative costs, professional fees, and stock-based compensation.

• Net loss for the period was $3,337,995, with the Drug Division accounting for 84% of the loss.

Outlook and guidance

• Plans to secure additional funding through equity and debt instruments in 2024 and 2025 to support completion of Study II and regulatory submissions.

• Targeting completion of Study II enrollment in 2025, data lock in mid-2026, and FDA/Health Canada approval by end of 2026, subject to priority review.